Platelet measurements versus discharge diagnoses for identification of patients with potential drug-induced thrombocytopenia: A cross-sectional study in the Netherlands

Drug Safety

Volumn 32, Issue 1, 2009, Pages 69-76

  Ten Berg, Maarten J ^a,b   Van Solinge, Wouter W ^a,b   Van Den Bemt, Patricia M L A ^a,c   Huisman, Albert ^b   Schobben, Alfred F A M ^a,b   Egberts, Toine C G ^a,b  

^a UTRECHT UNIVERSITY   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG;

ARTICLE; COMPARATIVE STUDY; HOSPITAL DISCHARGE; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; NETHERLANDS; PATIENT IDENTIFICATION; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

CROSS-SECTIONAL STUDIES; DATABASES, FACTUAL; HOSPITALS, UNIVERSITY; HUMANS; INTERNATIONAL CLASSIFICATION OF DISEASES; NETHERLANDS; PATIENT DISCHARGE; PHARMACEUTICAL PREPARATIONS; PHARMACOEPIDEMIOLOGY; PLATELET FUNCTION TESTS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; THROMBOCYTOPENIA;

EID: 58149343556     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200932010-00006     Document Type: Article

References (26)

1. Kelly WN. Potential risks and prevention, part 1: fatal adverse drug events. Am J Health Syst Pharm 2001; 58 (14): 1317-24
2. Fung M, Thornton A, Mybeck K, et al. Evaluation of the characteristics of safety withdrawals of prescription drugs from worldwide pharmaceutical markets: 1960 to 1999. Drug Inf J 2001; 35: 293-317
3. Rawson NS, Harding SR, Malcolm E, et al. Hospitalizations for aplastic anemia and agranulocytosis in Saskatchewan: incidence and associations with antecedent prescription drug use. J Clin Epidemiol 1998; 51 (12): 1343-55
4. van der Klauw MM, Goudsmit R, Halie MR, et al. A population-based case-cohort study of drug-associated agranulocytosis. Arch Intern Med 1999; 159 (4): 369-74
5. Huerta C, Garcia Rodriguez LA. Risk of clinical blood dyscrasia in a cohort of antibiotic users. Pharmacotherapy 2002; 22 (5): 630-6
6. van Staa TP, Boulton F, Cooper C, et al. Neutropenia and agranulocytosis in England and Wales: incidence and risk factors. Am J Hematol 2003; 72 (4): 248-54
7. ten Berg MJ, Huisman A, Souverein PC, et al. Drug-induced thrombocytopenia: a population study. Drug Saf 2006; 29 (8): 713-21
8. Handoko KB, Souverein PC, van Staa TP, et al. Risk of aplastic anemia in patients using antiepileptic drugs. Epilepsia 2006; 47 (7): 1232-6
9. Risks of agranulocytosis and aplastic anemia: a first report of their relation to drug use with special reference to analgesics. The International Agranulocytosis and Aplastic Anemia Study. JAMA 1986; 256 (13): 1749-57
10. CDC National Center for Health Statistics. International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) [online]. Available from URL: http://www.cdc.gov/nchs/about/otheract/icd9/abticd9.htm [Accessed 2008 Jul 10]
11. Strom BL. Overview of automated databases in pharmacoepidemiology. In: Strom BL, editor. Pharmacoepidemiology. 4th ed. Chichester: John Wiley & Sons Ltd, 2005: 219-22
12. Herings RM, Bakker A, Stricker BH, et al. Pharmacomorbidity linkage: a feasibility study comparing morbidity in two pharmacy based exposure cohorts. J Epidemiol Community Health 1992; 46 (2): 136-40
13. ten Berg MJ, Huisman A, van den Bemt PM, et al. Linking laboratory and medication data: new opportunities for pharmacoepidemiological research. Clin Chem Lab Med 2007; 45 (1): 13-9
14. van den Bemt PM, Meyboom RH, Egberts AC. Drug-induced immune thrombocytopenia. Drug Saf 2004; 27 (15): 1243-52
15. Benichou C, Solal-Céligny P. Standardization of definitions and criteria of causality assessment of adverse drug reactions. Drug-induced cytopenia. Int J Clin Pharmacol Ther Toxicol 1991; 29 (2): 75-81
16. George JN, Raskob GE, Shah SR, et al. Drug-induced thrombocytopenia: a systematic review of published case reports. Ann Intern Med 1998; 129 (11): 886-90
17. CBV Foundation. About the Classification of Medical Specialist Procedures (CMSV) [in Dutch; online]. Available from URL: http://www.cbv.nl [Accessed 2008 Jul 10]
18. McCrae KR. Thrombocytopenia. New York: Taylor & Francis, 2006
19. Liles DK, Knupp CL. Disorders of primary hemostasis, quantitative and qualitative platelet disorders and vascular disorders. In: Harmening DM, editor. Clinical hematology and fundamentals of hemostasis. 4th ed. Philadelphia (PA): F.A. Davis Company, 2002: 471-94
20. Gresele P, Page C, Fuster V, et al. Platelets in thrombotic and non-thrombotic disorders pathophysiology, pharmacology and therapeutics. Cambridge: Cambridge University Press, 2002
21. Solal-Céligny P. Abnormal hematologic values. In: Bénichou C, editor. Adverse drug reactions: a practical guide to diagnosis and management. Chichester: John Wiley & Sons, 1994: 13-30
22. Movig KL, Leufkens HG, Lenderink AW, et al. Validity of hospital discharge International Classification of Diseases (ICD) codes for identifying patients with hyponatremia. J Clin Epidemiol 2003; 56 (6): 530-5
23. Azaz-Livshits T, Levy M, Sadan B, et al. Computerized surveillance of adverse drug reactions in hospital: pilot study. Br J Clin Pharmacol 1998; 45 (3): 309-14
24. Levy M, Azaz-Livshits T, Sadan B, et al. Computerized surveillance of adverse drug reactions in hospital: implementation. Eur J Clin Pharmacol 1999; 54 (11): 887-92
25. Tegeder I, Levy M, Muth-Selbach U, et al. Retrospective analysis of the frequency and recognition of adverse drug reactions by means of automatically recorded laboratory signals. Br J Clin Pharmacol 1999; 47 (5): 557-64
26. Petitti DB, Contreras R, Glowalla M, et al. Most severe neutropenia in individuals with no chronic condition did not result in a specific diagnosis. J Clin Epidemiol 2004; 57 (11): 1182-7